Traditionally, response evaluation for NSCLC patients harboring EGFR mutations treated with TKIs is usually based on anatomic imaging features that mainly present with static, and calculating the change of tumor size on CT and using Response Evaluation Criteria in Solid Tumors (RECIST) for classification (76, 77). Here, EGFR is linked to neoplasm.